Philippe Merle

30.3k total citations · 5 hit papers
207 papers, 9.1k citations indexed

About

Philippe Merle is a scholar working on Hepatology, Oncology and Epidemiology. According to data from OpenAlex, Philippe Merle has authored 207 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Hepatology, 89 papers in Oncology and 54 papers in Epidemiology. Recurrent topics in Philippe Merle's work include Hepatocellular Carcinoma Treatment and Prognosis (117 papers), Colorectal Cancer Treatments and Studies (38 papers) and Hepatitis B Virus Studies (32 papers). Philippe Merle is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (117 papers), Colorectal Cancer Treatments and Studies (38 papers) and Hepatitis B Virus Studies (32 papers). Philippe Merle collaborates with scholars based in France, United States and Italy. Philippe Merle's co-authors include Masatoshi Kudo, Ann‐Lii Cheng, Richard S. Finn, В. В. Бредер, Andrew X. Zhu, Ho Yeong Lim, Jack R. Wands, Julien Edeline, Thomas Yau and Christian Trépo and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Philippe Merle

202 papers receiving 9.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

2019 1.3k citations Richard S. Finn, Baek‐Yeol Ryoo et al. Journal of Clinical Oncology profile →
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

2021 891 citations Ann‐Lii Cheng, Peter R. Galle et al. profile →
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

2019 497 citations Thomas Yau, Richard S. Finn et al. Annals of Oncology profile →
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

2021 229 citations Richard S. Finn, Peter R. Galle et al. Journal of Clinical Oncology profile →
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

2022 135 citations Masatoshi Kudo, Philippe Merle et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Philippe Merle

Since Specialization

Citations

This map shows the geographic impact of Philippe Merle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Merle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Merle more than expected).

Fields of papers citing papers by Philippe Merle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Merle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Merle. The network helps show where Philippe Merle may publish in the future.

Co-authorship network of co-authors of Philippe Merle

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Merle. A scholar is included among the top collaborators of Philippe Merle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Merle. Philippe Merle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240. 2024 ·Journal of Clinical Oncology ·Masatoshi Kudo, Ann‐Lii Cheng, Philippe Merle, Baek‐Yeol Ryoo, Thomas Decaens, İrfan Çiçin, Olav Dajani, Raed Moh’d Taiseer Al-Rajabi, Jean‐Marie Péron, Stephen L. Chan, Jennifer J. Knox, (unknown), (unknown), Andrea L. Webber, Carol E. Peña, Răzvan Cristescu, Cai Chen, Ken Hatogai, Abby B. Siegel, Richard S. Finn	1
2	International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI). 2024 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Tae‐You Kim, Jean‐Frédéric Blanc, Olivier Rosmorduc, Thomas Decaens, Philippe Mathurin, Philippe Merle, Farshid Dayyani, Gianluca Masi, Tiziana Pressiani, Peter R. Galle, Ken Hatogai, Yuko Ishii, Henrik Seidel, U. Mueller, Stacey Kalambakas, Mohamed Bouattour	13
3	Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150 2024 ·Liver Cancer ·Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann‐Lii Cheng, Norelle R. Reilly, Alan Nicholas, Sairy Hernandez, (unknown), Philippe Merle, Riad Salem, Daneng Li, В. В. Бредер	12
4	Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC). 2024 ·Journal of Clinical Oncology ·Philippe Merle, Jean-Marie Péron, Karine Le Malicot, (unknown), (unknown), Vincent Bourgeois, Eric Assénat, Jean‐Frédéric Blanc, Mohamed Bouattour, Yann Touchefeu, F. Khemissa Akouz, Éric Nguyen-Khac, Jean-Pierre Bronowicki, (unknown), (unknown), (unknown), Xavier Adhoute, Julien Edeline, Jean‐Charles Nault, Jean–Marc Phelip	1
5	Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review 2023 ·Liver Cancer ·Arndt Vogel, Robin Kate Kelley, Philip J. Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa	6
6	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial 2023 ·Liver Cancer ·Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann‐Lii Cheng, Stephen L. Chan, (unknown), Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martínez‐Forero, Ziwen Wei, (unknown), (unknown)	31
7	First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers 2022 ·Liver Cancer ·James J. Harding, Ahmad Awada, Gaël S. Roth, Thomas Decaens, Philippe Merle, Nuria Kotecki, Chantal Dreyer, (unknown), (unknown), Soraya Mezouar, (unknown), Eloïne Bestion, Valérie Paradis, Philippe Halfon, Ghassan K. Abou‐Alfa, Éric Raymond	16
8	Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial 2022 ·Liver Cancer ·Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo	18
9	Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety 2022 ·Liver Cancer ·Philippe Merle, Masatoshi Kudo, (unknown), (unknown), Yun Su, Irina Proskorovsky	8
10	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma 2021 ·Liver Cancer ·Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek‐Yeol Ryoo, Philippe Merle, Joong‐Won Park, Jean‐Frédéric Blanc, Ho Yeong Lim, Albert Tran, Yi‐Wah Chan, Paul R. McAdam, Evelyn N. Wang, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	22
11	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma 2020 ·Clinical Cancer Research ·Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, Philippe Merle, Joong‐Won Park, Thomas Yau, Stephen L. Chan, Jean‐Frédéric Blanc, Vincent C. Tam, Albert Tran, Vincenzo Dadduzio, David W. Markby, Rajesh Kaldate, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	66
12	PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles’ heel? 2020 ·Clinics and Research in Hepatology and Gastroenterology ·Laetitia Gérossier, A. Dubois, (unknown), Nadim Farés, (unknown), Philippe Merle, Joël Lachuer, Anne Wierinckx, Pierre Saintigny, Brigitte Bancel, Janick Sèlves, Anne Schnitzler, Bérengère Ouine, (unknown), Leanne de Koning, (unknown), Ivan Bièche, Héctor Hernández‐Vargas, Janet Hall, Isabelle Chemin	12
13	Comparison and analysis of the efficacy of drug therapy for liver cancer 2020 ·Hepatoma Research ·Philippe Merle, Miroslava Subic	3
14	Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240 2020 ·Cancer ·Baek‐Yeol Ryoo, Philippe Merle, Amit S. Kulkarni, Ann‐Lii Cheng, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Bruno Daniele, Josephine M. Norquist, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Richard S. Finn, Masatoshi Kudo	25
15	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial breakdown → 2019 ·Journal of Clinical Oncology ·Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng, (unknown)	1300
16	Systemic Treatment Options in Hepatocellular Carcinoma 2019 ·Liver Cancer ·Lorenza Rimassa, Tiziana Pressiani, Philippe Merle	91
17	Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial 2019 ·Radiology ·Boris Guiu, P. Chevallier, Eric Assénat, Emilie Barbier, Philippe Merle, Antoine Bouvier, Jérôme Dumortier, Éric Nguyen-Khac, Jean Gugenheim, Agnès Rode, Frédéric Oberti, Pierre‐Jean Valette, Thierry Yzet, Olivier Chevallier, Jean‐Claude Barbare, Marianne Latournerie, Mathieu Boulin	27
18	Response to the Comments on Rimassa et al.: “Systemic Treatment Options in Hepatocellular Carcinoma” 2019 ·Liver Cancer ·Lorenza Rimassa, Tiziana Pressiani, Philippe Merle	2
19	Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) 2018 ·Annals of Oncology ·Thomas Yau, Philippe Merle, Lorenza Rimassa, Baek‐Yeol Ryoo, (unknown), William Proctor Harris, Eugéniu Banu, Debashis Sarker, Benjamin Tan, Hans Van Vlierberghe, Seema Sen, (unknown), Ann‐Lii Cheng, T Meyer, Robin Kate Kelley, Ghassan K. Abou‐Alfa	4
20	PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus–Induced Liver Carcinogenesis 2015 ·Cancer Research ·Hao Zhang, Ahmed Diab, Huitao Fan, Saravana Kumar Kailasam Mani, Ronald L. Hullinger, Philippe Merle, Ourania Andrisani	115

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact